CNRS Aug 28 2024 CNRS Scientists have deciphered the activation pathway of bemnifosbuvir, a drug candidate initially in development to treat hepatitis C virus (HCV). The findings of the research team, led by CNRS scientists, unlock new opportunities to boost the efficacy of this type of drug against other RNA viruses, such as the ones that cause Covid-19 and dengue fever. When taken in pill form, bemnifosbuvir - like all antivirals in the same family - must undergo a series of changes inside

Tag-uri: Coronavirus